Teva secures new $1.5 billion credit line
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has entered into a new three-year, $1.5 billion unsecured revolving credit facility, which replaces and expands existing credit lines at "more favourable" terms, according to the Israel-based generics giant.